Abstract
Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.
Original language | English (US) |
---|---|
Pages (from-to) | 518-521 |
Number of pages | 4 |
Journal | European Psychiatry |
Volume | 27 |
Issue number | 7 |
DOIs | |
State | Published - Oct 2012 |
Externally published | Yes |
Keywords
- Cognitive function
- Major depression
- One-carbon cycle
- Pharmacotherapy
- S-adenosylmethionine
ASJC Scopus subject areas
- Psychiatry and Mental health